Smoking is associated with increased risk of myeloproliferative neoplasms

A general population‐based cohort study

Kasper M. Pedersen, Marie Bak, Anders L. Sørensen, Ann-Dorthe Zwisler, Christina Ellervik, Morten Kranker Larsen, Hans Hasselbalch, Janne Schurmann Tolstrup

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Background: Former studies on smoking as a risk factor for Philadelphia‐negative myeloproliferative neoplasms (MPNs) have mainly been carried out in women’s cohorts and studies with various definitions of MPNs. Herein, we conducted a cohort study with register‐based follow‐up of a general population from Denmark, to validate and substantiate prior observations. Methods: In the Danish Health Examination Survey cohort, we used the Cox proportional‐hazards model adjusted for age, sex, body mass index, and level of education, to calculate hazard ratios (HRs), to investigate, whether daily smokers or occasional/ ex‐smokers had an increased risk of MPNs compared to never‐smokers. Results: From the time of data collection (September 2007 to October 2008) until 1 January 2015, 70 individuals were diagnosed with MPNs among 75 896 study participants. Similar results were observed in both the age and sex adjusted analysis and the multivariable analysis. The multivariable HR of any MPN diagnosis for daily smokers was 2.5 (95% CI: 1.3‐5.0). For essential thrombocytosis, polycythemia vera, myelofibrosis, and MPN‐unclassified, the HRs were 1.8 (95% CI: 0.5‐5.8), 1.7 (95% CI: 0.5‐5.8), 4.3 (95% CI: 0.9‐19), and 6.2 (95% CI: 1.5‐25), respectively. Among occasional/ex‐smokers the corresponding HRs were 1.9 (95% CI: 1.1‐3.3), 1.5 (95% CI: 0.6‐3.7), 0.8 (95% CI: 0.3‐2.4), 0.9 (95% CI: 0.2‐4.4), and 6.2 (95% CI: 1.8‐21). Participants, who smoked >15 g/day, had an overall HR of 3.4 (95% CI: 1.4‐8.2) for any MPN diagnosis, while participants who smoked ≤15 g/day, had an overall HR of 2.1 (95% CI: 0.9‐4.7). Conclusion: Smoking was associated with MPN development when comparing smokers and never‐smokers. Further studies investigating smoking in MPNs are warranted to substantiate our findings.
OriginalsprogEngelsk
TidsskriftCancer Medicine
Vol/bind7
Sider (fra-til)5796–5802
DOI
StatusUdgivet - 2018

Emneord

  • epidemiology
  • essential thrombocythemia
  • myeloproliferative neoplasms
  • polycythemia vera
  • primary myelofibrosis
  • tobacco smoking

Citer dette

Pedersen, K. M., Bak, M., Sørensen, A. L., Zwisler, A-D., Ellervik, C., Larsen, M. K., ... Tolstrup, J. S. (2018). Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study. Cancer Medicine, 7, 5796–5802. https://doi.org/10.1002/cam4.1815
Pedersen, Kasper M. ; Bak, Marie ; Sørensen, Anders L. ; Zwisler, Ann-Dorthe ; Ellervik, Christina ; Larsen, Morten Kranker ; Hasselbalch, Hans ; Tolstrup, Janne Schurmann. / Smoking is associated with increased risk of myeloproliferative neoplasms : A general population‐based cohort study. I: Cancer Medicine. 2018 ; Bind 7. s. 5796–5802.
@article{6017b0ec3b344dd19256e4a96d48950f,
title = "Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study",
abstract = "Background: Former studies on smoking as a risk factor for Philadelphia‐negative myeloproliferative neoplasms (MPNs) have mainly been carried out in women’s cohorts and studies with various definitions of MPNs. Herein, we conducted a cohort study with register‐based follow‐up of a general population from Denmark, to validate and substantiate prior observations. Methods: In the Danish Health Examination Survey cohort, we used the Cox proportional‐hazards model adjusted for age, sex, body mass index, and level of education, to calculate hazard ratios (HRs), to investigate, whether daily smokers or occasional/ ex‐smokers had an increased risk of MPNs compared to never‐smokers. Results: From the time of data collection (September 2007 to October 2008) until 1 January 2015, 70 individuals were diagnosed with MPNs among 75 896 study participants. Similar results were observed in both the age and sex adjusted analysis and the multivariable analysis. The multivariable HR of any MPN diagnosis for daily smokers was 2.5 (95{\%} CI: 1.3‐5.0). For essential thrombocytosis, polycythemia vera, myelofibrosis, and MPN‐unclassified, the HRs were 1.8 (95{\%} CI: 0.5‐5.8), 1.7 (95{\%} CI: 0.5‐5.8), 4.3 (95{\%} CI: 0.9‐19), and 6.2 (95{\%} CI: 1.5‐25), respectively. Among occasional/ex‐smokers the corresponding HRs were 1.9 (95{\%} CI: 1.1‐3.3), 1.5 (95{\%} CI: 0.6‐3.7), 0.8 (95{\%} CI: 0.3‐2.4), 0.9 (95{\%} CI: 0.2‐4.4), and 6.2 (95{\%} CI: 1.8‐21). Participants, who smoked >15 g/day, had an overall HR of 3.4 (95{\%} CI: 1.4‐8.2) for any MPN diagnosis, while participants who smoked ≤15 g/day, had an overall HR of 2.1 (95{\%} CI: 0.9‐4.7). Conclusion: Smoking was associated with MPN development when comparing smokers and never‐smokers. Further studies investigating smoking in MPNs are warranted to substantiate our findings.",
keywords = "epidemiology, essential thrombocythemia, myeloproliferative neoplasms, polycythemia vera, primary myelofibrosis, tobacco smoking, epidemiology, essential thrombocythemia, myeloproliferative neoplasms, polycythemia vera, primary myelofibrosis, tobacco smoking",
author = "Pedersen, {Kasper M.} and Marie Bak and S{\o}rensen, {Anders L.} and Ann-Dorthe Zwisler and Christina Ellervik and Larsen, {Morten Kranker} and Hans Hasselbalch and Tolstrup, {Janne Schurmann}",
year = "2018",
doi = "10.1002/cam4.1815",
language = "English",
volume = "7",
pages = "5796–5802",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "JohnWiley & Sons Ltd.",

}

Pedersen, KM, Bak, M, Sørensen, AL, Zwisler, A-D, Ellervik, C, Larsen, MK, Hasselbalch, H & Tolstrup, JS 2018, 'Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study', Cancer Medicine, bind 7, s. 5796–5802. https://doi.org/10.1002/cam4.1815

Smoking is associated with increased risk of myeloproliferative neoplasms : A general population‐based cohort study. / Pedersen, Kasper M.; Bak, Marie; Sørensen, Anders L.; Zwisler, Ann-Dorthe; Ellervik, Christina; Larsen, Morten Kranker; Hasselbalch, Hans; Tolstrup, Janne Schurmann.

I: Cancer Medicine, Bind 7, 2018, s. 5796–5802.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Smoking is associated with increased risk of myeloproliferative neoplasms

T2 - A general population‐based cohort study

AU - Pedersen, Kasper M.

AU - Bak, Marie

AU - Sørensen, Anders L.

AU - Zwisler, Ann-Dorthe

AU - Ellervik, Christina

AU - Larsen, Morten Kranker

AU - Hasselbalch, Hans

AU - Tolstrup, Janne Schurmann

PY - 2018

Y1 - 2018

N2 - Background: Former studies on smoking as a risk factor for Philadelphia‐negative myeloproliferative neoplasms (MPNs) have mainly been carried out in women’s cohorts and studies with various definitions of MPNs. Herein, we conducted a cohort study with register‐based follow‐up of a general population from Denmark, to validate and substantiate prior observations. Methods: In the Danish Health Examination Survey cohort, we used the Cox proportional‐hazards model adjusted for age, sex, body mass index, and level of education, to calculate hazard ratios (HRs), to investigate, whether daily smokers or occasional/ ex‐smokers had an increased risk of MPNs compared to never‐smokers. Results: From the time of data collection (September 2007 to October 2008) until 1 January 2015, 70 individuals were diagnosed with MPNs among 75 896 study participants. Similar results were observed in both the age and sex adjusted analysis and the multivariable analysis. The multivariable HR of any MPN diagnosis for daily smokers was 2.5 (95% CI: 1.3‐5.0). For essential thrombocytosis, polycythemia vera, myelofibrosis, and MPN‐unclassified, the HRs were 1.8 (95% CI: 0.5‐5.8), 1.7 (95% CI: 0.5‐5.8), 4.3 (95% CI: 0.9‐19), and 6.2 (95% CI: 1.5‐25), respectively. Among occasional/ex‐smokers the corresponding HRs were 1.9 (95% CI: 1.1‐3.3), 1.5 (95% CI: 0.6‐3.7), 0.8 (95% CI: 0.3‐2.4), 0.9 (95% CI: 0.2‐4.4), and 6.2 (95% CI: 1.8‐21). Participants, who smoked >15 g/day, had an overall HR of 3.4 (95% CI: 1.4‐8.2) for any MPN diagnosis, while participants who smoked ≤15 g/day, had an overall HR of 2.1 (95% CI: 0.9‐4.7). Conclusion: Smoking was associated with MPN development when comparing smokers and never‐smokers. Further studies investigating smoking in MPNs are warranted to substantiate our findings.

AB - Background: Former studies on smoking as a risk factor for Philadelphia‐negative myeloproliferative neoplasms (MPNs) have mainly been carried out in women’s cohorts and studies with various definitions of MPNs. Herein, we conducted a cohort study with register‐based follow‐up of a general population from Denmark, to validate and substantiate prior observations. Methods: In the Danish Health Examination Survey cohort, we used the Cox proportional‐hazards model adjusted for age, sex, body mass index, and level of education, to calculate hazard ratios (HRs), to investigate, whether daily smokers or occasional/ ex‐smokers had an increased risk of MPNs compared to never‐smokers. Results: From the time of data collection (September 2007 to October 2008) until 1 January 2015, 70 individuals were diagnosed with MPNs among 75 896 study participants. Similar results were observed in both the age and sex adjusted analysis and the multivariable analysis. The multivariable HR of any MPN diagnosis for daily smokers was 2.5 (95% CI: 1.3‐5.0). For essential thrombocytosis, polycythemia vera, myelofibrosis, and MPN‐unclassified, the HRs were 1.8 (95% CI: 0.5‐5.8), 1.7 (95% CI: 0.5‐5.8), 4.3 (95% CI: 0.9‐19), and 6.2 (95% CI: 1.5‐25), respectively. Among occasional/ex‐smokers the corresponding HRs were 1.9 (95% CI: 1.1‐3.3), 1.5 (95% CI: 0.6‐3.7), 0.8 (95% CI: 0.3‐2.4), 0.9 (95% CI: 0.2‐4.4), and 6.2 (95% CI: 1.8‐21). Participants, who smoked >15 g/day, had an overall HR of 3.4 (95% CI: 1.4‐8.2) for any MPN diagnosis, while participants who smoked ≤15 g/day, had an overall HR of 2.1 (95% CI: 0.9‐4.7). Conclusion: Smoking was associated with MPN development when comparing smokers and never‐smokers. Further studies investigating smoking in MPNs are warranted to substantiate our findings.

KW - epidemiology

KW - essential thrombocythemia

KW - myeloproliferative neoplasms

KW - polycythemia vera

KW - primary myelofibrosis

KW - tobacco smoking

KW - epidemiology

KW - essential thrombocythemia

KW - myeloproliferative neoplasms

KW - polycythemia vera

KW - primary myelofibrosis

KW - tobacco smoking

U2 - 10.1002/cam4.1815

DO - 10.1002/cam4.1815

M3 - Journal article

VL - 7

SP - 5796

EP - 5802

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -